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Case Report
Variably protease-sensitive prionopathy mimicking
frontotemporal dementia
Miren Aizpurua,1 Sashika Selvackadunco,2 Helen Yull,3 Christopher M. Kipps,4,5 James W. Ironside3
and Istvan Bodi1,2
1Clinical Neuropathology, King’s College Hospital, NHS Foundation Trust, 2London Neurodegenerative Diseases Brain
Bank, IOPPN, London, 3National Creutzfeldt-Jakob Disease Research & Surveillance Unit, Centre for Clinical Brain
Sciences, University of Edinburgh, Edinburgh, 4Wessex Neurological Centre, University Hospital Southampton NHS
Foundation Trust and 5Clinical Neurosciences, University of Southampton, Southampton, UK
Sporadic prion diseases are fatal neurodegenerative disor-
ders characterized clinically by rapidly progressive dementia
and myoclonus. Variably protease-sensitive prionopathy
(VPSPr) is a recently identiﬁed sporadic human prion disor-
der that may present with a lengthy atypical clinical history.
Here, we describe a case of VPSPr in a patient with a
long history of suspected frontotemporal dementia (FTD).
A 61-year-old man presented with speech difﬁculties,
including naming objects and constructing multipart sen-
tences, while there was no difﬁculty in comprehension.
Movement abnormalities included slightly jerky pursuit,
minor dysmetria of saccades and brisk reﬂexes. There was
no family history of dementia. Later he developed
swallowing difﬁculties and the possibility of FTD with motor
neuron disease was suspected. He died at the age of 71 and
his brain was donated to the London Neurodegenerative
Diseases Brain Bank. The brain (1004 g) showed mild to
moderate atrophy, predominantly in the frontal lobe. His-
tology revealed moderate spongiform microvacuolation
mostly affecting the frontal and parietal cortices, but also
present focally in the basal ganglia and the cerebellum. Only
mild Alzheimer pathology was found by extensive immuno-
histochemistry, in keeping with BrainNet Europe stage
II. Trans-activation response DNA-binding protein 43 kDa
and α-synuclein immunostains were negative. Immuno-
staining for prion protein (PrP) showed granular/synaptic
positivity in a patchy distribution, mainly within the deeper
cortex, and also revealed microplaques in the cerebellum
and basal ganglia. Western blotting conﬁrmed a low molec-
ular weight protease-resistant PrP band with a faint ladder-
like pattern in the absence of types 1 and 2 isoforms. These
features are diagnostic of VPSPr. VPSPr can mimic various
neurodegenerative conditions; diagnosis requires both PrP
immunohistochemistry and Western blotting. The presence
of patchy spongiform change in the absence of other neuro-
degenerative pathology should raise suspicion of VPSPr,
even in elderly patients with a lengthy clinical history.
Key words: Creutzfeldt–Jakob disease, prions, prion dis-
eases, prionprotein, variablyprotease-sensitiveprionopathy.
INTRODUCTION
Human prion diseases are fatal neurodegenerative disor-
ders that are characterized neuropathologically by the
abnormal accumulation of a misfolded prion protein (PrP)
in the central nervous system. The mechanism by which
the cellular PrP (PrPC) is converted into the pathogenic
scrapie-type PrP (PrPSc) appears to involve a post-
translational change in PrPC conformation, from a predom-
inantly α-helical into a predominantly β-sheet structure.1
PrPSc is the major, if not the sole, component of the trans-
missible agent in prion diseases. PrPSc is relatively insolu-
ble and aggregates extracellularly, possibly inducing
adjacent tissue malfunction, although the exact pathologi-
cal mechanism is still unclear. Human prion diseases differ
not only in their clinical and neuropathological features,
but also in the biochemical features (differential glycosyla-
tion and relatively resistance to proteinase digestion) of
PrPSc in the brain, making prionopathies a much more het-
erogeneous group of disorders than initially considered.
Human prion diseases are classiﬁed into three main cate-
gories: sporadic, acquired or genetic (familial). Sporadic
Creutzfeldt–Jakob disease (sCJD) is the most common
human prion disease, occurring world-wide and characterized
clinically by rapidly progressive dementia and myoclonus.
However, sCJD is known to be clinically and pathologically
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heterogeneous, and is currently sub-classiﬁed into six sub-
types.2 The molecular basis for this heterogeneity is thought
to correspond to an interaction between the naturally occur-
ring methionine/valine polymorphism at codon 129 of the
prion protein gene (PRNP) (MM, MV, or VV) and the
abnormal prion protein isoform in the brain, as determined
by Western blot analysis of the protease-resistant band (ter-
med PrPres) obtained by treating PrPSc with protease K. The
resulting bands are then classiﬁed by their molecular weight
as type 1 or type 2.3,4 Recent investigations have identiﬁed
another sporadic human prion disease, termed variably
protease-sensitive prionopathy (VPSPr) which lacks PRNP
mutations but is clinically and biochemically different from
sporadic CJD.5 Here, we report a case of VPSPr in a UK
patient with a lengthy clinical history mimicking
frontotemporal dementia.
CLINICAL SUMMARY
Brain donation to the London Neurodegenerative Diseases
Brain Bank for research was received from a 71-year-old
man. He presented at the age of 69 with 8 years history of
speech difﬁculties. He apparently had a stressful time some
years ago when selling his company and noticed that his
speech was less ﬂuent and he became prone to making dys-
phasic errors. He also noticed a slight change in handwrit-
ing. Although the onset of the disease was very slow, his
partner did highlight a substantial change in his attention,
some degree of repetitive questioning and memory distur-
bances such as loosing or misplacing objects and forgetting
the names of people and objects. He lost track of his
thoughts if he was interrupted; however, there was no topo-
graphical disorientation. He had no difﬁculty with self-care
and there were no mood or behavioral disturbance,
although a slight reduction in motivation was observed. No
visual hallucinations were reported. There was no family
history of neurological disease. On examination, a mild
expressive dysphasia with a degree of orobuccal apraxia was
observed; his speech was prone to error with longer words
and he had difﬁculty in repeating polysyllabic words and
multipart sentences, but there was no difﬁculty with compre-
hension. There were no visuospatial errors, but he had difﬁ-
culty with writing and some spelling limitations. There were
no parkinsonian signs, but there was slightly jerky pursuit
both horizontally and vertically as well as possibly minor
dysmetria of saccades. There were occasional limb muscle
fasciculations without associated weakness. His Mini-Mental
State Examination was 26/30 and cognitive examination
(ACE-R) score of 84/100. magnetic resonance imaging
showed generalized involutional change and several non-
speciﬁc high signal lesions. The clinical features favored pri-
mary progressive non-ﬂuent aphasia (PPA) and
hexylmethylpropylene amineoxine – single-photon emission
computed tomography scan showed an inferior frontal
hypoperfusion, in keeping with PPA in September 2014
(Fig. 1). Nerve conduction studies identiﬁed benign fascicu-
lations, but nothing consistent with motor neuron disease
(MND). Genetic testing for C9orf72 was negative. His neu-
rodegenerative condition progressed following presentation,
and he developed swallowing difﬁculties, subsequent aspira-
tion pneumonias as well as seizures. He died at age
71, 10 years after the initial presentation.
PATHOLOGICAL FINDINGS
According to our brain bank protocol the right half of the
brain was sampled fresh and stored in a freezer at −80C,
while the left half of the brain was ﬁxed in formalin and
processed for neuropathological examination. The fresh
brain weight was 1004 g; the formalin ﬁxed left brain
weighed 509 g and the left brainstem and cerebellum hemi-
sphere weighed 90 g. There was mild to moderate general-
ized cortical atrophy, slightly more prominent in the frontal
lobe and around the Sylvian ﬁssure. Mild ventricular dilata-
tion and a slightly smaller hippocampus were also seen.
Histology of the brain revealed mild to moderate neuronal
loss in the neocortex, particularly in the frontal and parieto-
occipital lobes. This was associated with microvacuolation,
often involving the deeper cortical layers, and no areas of con-
ﬂuent spongiform change were identiﬁed (Fig. 2A–C). The
Fig. 1 99mTc – hexylmethylpropyl-
ene amineoxine – single-photon emis-
sion computed tomography scan of
subject’s cerebral perfusion compared
against age-matched controls, rendered
on template brain atP < 0.01 threshold.
Scan shows predominant left dorsolat-
eral prefrontal cortex and insula hypo-
perfusion consistent with a non-ﬂuent
aphasic syndrome.
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microvacuolation was also noticeable in the basal ganglia,
medial thalamic nuclei and the cerebellar cortex, while the
hippocampus and the brainstem were relatively spared.
Despite the neuronal loss, the overall Alzheimer-type changes
were relatively mild by extensive immunohistochemistry.
Amyloid-β (Millipore, Watford, UK) deposition was more
widespread, in keeping with Thal phase 3 and Consortium to
Establish a Registry for Alzheimer Disease plaque stage
A. There was no signiﬁcant amyloid angiopathy, although a
few leptomeningeal blood vessels were labelled by amyloid-β.
Fig. 2 Microphotographs of sections stained with hematoxylin and eosin from the cerebellum (A), putamen (B), and occipital cortex
(C) as well as sections immunostained for PrP (12F10) from the cerebellum (D) and parietal (E) and occipital (F) cortices. Some neuro-
nal loss and variable degree of spongiform changes are seen, ranging from a few and isolated microvacuoles in the cerebellum (A) to
large coalescent vacuoles in the putamen (B). Transcortical microvacuolation is seen in the occipital cortex (C). PrP immunoreactivity is
localized in microplaques in the molecular layer of the cerebellum (D). There is a granular/synaptic pattern in the parietal (E) and occip-
ital (F) cortices, often in a patchy distribution. Scale bars: 50 μm (A-F).
Fig. 3 Western blots of PrP in the parietal cortex (left panel) as well as frontal (FC), temporal (TC), parietal (PC), occipital (OC) corti-
ces and cerebellum (Cb) (right panel). Samples from this case is analyzed without (−) and with (+) proteinase K (PK) digestion (50 μg/
μL, 1 h, 37C) (left panel). Samples from different regions are analyzed following PK digestion (right panel). The sample volumes (μL)
loaded are indicated; square brackets indicate samples that have undergone centrifugal concentration (each panel). The samples from
sCJD MM1 (1A), vCJD (2B) and sCJD VV2 (2A) are compared with PK-digested standards (each panel). The low-molecular weight
(LMWt) bands evident in this case are marked with arrows.
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The hyperphosphorylated tau (ThermoFisher Scientiﬁc,
Lutterworth, UK) positive pathology was relatively mild,
in keeping with BrainNet Europe (BNE) stage II (NIA-
ABC: A2, B1, C0). Phosphorylated trans-activation
response DNA-binding protein 43 kDa (ProteinTech,
Manchester, UK) and α-synuclein (BD Biosciences,
Wokingham, UK) immunostains were negative.
Immunohistochemistry for PrP showed very similar pat-
tern using the 12F10 (kindly supplied by Professor
Hunsmann of the German Primate Centre, Gottingen, Ger-
many) and 3F4 (Dako, Ely, UK) anti-PrP antibodies, reveal-
ing granular/synaptic pattern of accumulation in the cerebral
cortex, often in a patchy distribution and particularly in the
deeper cortical layers (Fig. 2D–F). There was also labelling
in the hippocampus, the basal ganglia and the thalamus.
Large numbers of microplaques were seen in the putamen
and the cerebellar cortex, particularly within the molecular
layer extending up to the subpial regions. No kuru-type
plaques were identiﬁed in the cerebellum on hematoxylin
and eosin staining or PrP immunohistochemistry.
Analysis of the frozen brain tissue by Western blotting
revealed a low molecular weight band in the frontal, tem-
poral, parietal and occipital cortices (Fig. 3). A similar band
was present at lesser intensity in the cerebellar cortex and a
faint ladder-like pattern, in the absence of types 1 and
2 isoforms, was also observed in the temporal parietal and
occipital cortices. This pattern is diagnostic of VPSPr.
Genetic analysis of the codon 129 polymorphism showed
valine homozygosity and no mutations in the PrP gene.
DISCUSSION
Gambetti et al.5 in 2008 (USA) reported 11 subjects affected
by a distinct prionopathy that differed biochemically and
clinically from the other sporadic prionopathies and was
characterized by the accumulation of a protease-sensitive
misfolded PrP. Since then, some other cases have been
described worldwide, demonstrating a higher incidence than
initially thought; further cases of VPSPr have been identi-
ﬁed prospectively and retrospectively in the USA,6,7
UK,8–10 the Netherlands,11 Austria12 and Spain.13–15 To date
altogether 39 VPSPr cases have been published.
Most sporadic prion diseases are characterized by two
main PrPres strains that vary from 21 to 19 kDa fragments
obtained after PrPSc proteinase K treatment: types 1 and
2 PrPres, respectively. These two subtypes have been experi-
mentally reported to be associated with a variable quantity
of another disease-associated PrP isoform that differs from
PrPc and PrPres in that this PrP strain is insoluble but highly
sensitive to proteinase K treatment, henceforth referred to
as PrPsen. Although both sCJD and sporadic fatal insomnia
(sFI) reveal types 1 or 2 PrPres isoforms and a small amount
of PrPsen on Western blotting, VPSPr is characterized by
the presence of various isoforms of PrPsen in the absence of
type 1 or 2 PrPres isoforms.16 The most interesting aspect of
this new disease from a biochemical point of view is that
although PrPSc is abundantly present in the brain, conven-
tional PrPres isoforms are difﬁcult to detect on Western blot-
ting because of their relatively increased sensitivity to
proteolysis. PrPsen consists of a C- and N-terminally trun-
cated approximately 8 kDa band that is usually accompa-
nied by a ladder of bands that extend between 18 and
30 kDa in range on Western blotting. Moreover, the ladder-
like pattern appears to be dependent on the codon 129 geno-
type, which adds more complexity to the biochemical
features of VPSPr. Indeed, it has been reported that the
electrophoretic migration features of the protease-resistant
bands, and thus the ladder-like proﬁle intensity on Western
blotting, vary depending upon the PRNP codon 129 geno-
types. It appears that 129MM shows the most intense
ladder-like composition, reﬂecting a higher PK resistance,
whereas 129VV reveals a strong approximately 8 kDa band
but faint accompanying ladder-like bands, hence a lower
protease resistance.6 The current case revealed biochemical
features similar to those found in VPSPr 129VV; PRNP
codon valine homozygosity in our patient was later con-
ﬁrmed by genetic analysis. Not only is the PRNP codon
129 genotype related to a speciﬁc electrophoretic pattern,
but this genotype also inﬂuences the clinical presentation
and neuropathological features of VPSPr.16
With regard to the clinical presentation, VPSPr appears
to be also different from the other sporadic prionopathies.
Sporadic prion diseases, such as sCJD and sFI, are clini-
cally characterized by a rapidly progressive dementia and
myoclonus2 or in the case of sFI, by a progressive insom-
nia, psychiatric disturbances and a relatively short history
of dementia. However, VPSPr shows a much lengthier
course of disease than either sCJD or sFI. The presenting
symptoms consist of a predominantly fronto-temporal type
of dementia with or without Parkinsonism in the absence
of sleep disturbances or involuntary muscle contractions.16
The disease progresses toward the development of motor
abnormalities, worsening of the initial symptoms and
ﬁnally enters into an akinetic-mutism period. Again,
depending upon the PRNP codon 129 status, the pre-
senting symptoms will vary; 129VV cases (25/37 conﬁrmed
VPSPr), usually reveal a more psychiatric, speech and
cognitive-associated initial decline, whereas the 129MM
(5/37 conﬁrmed VPSPr) and 129MV (9/38 conﬁrmed
VPSPr) counterparts may not be symptomatic at all (two
of the MM cases) or present with more parkinsonian fea-
tures and fewer behavioral disturbances.6,17 With regard
to the patient described here, the presentation was a long
history of language difﬁculties, with very mild mood dis-
turbances and no signs of parkinsonism or myoclonus.
Although there was a minimal memory decline in the
© 2019 The Authors. Neuropathology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of
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beginning, this has only been found to be present at onset
in 50% of 129VV cases.6 Unlike 129MM and 129MV
genotypes, 129VV does not usually present with parkinso-
nian features, as in our case. However, as the disease
progressed, the patient did show gait disturbances which
led him to suffer from several falls and also develop other
symptoms that have yet not been linked to any of the
genotypes, such as seizures or dysphagia. As seen in 50%
of 129VV patients, there was no family history of demen-
tia. The patient died approximately 10 years after the
onset of the symptoms.
From a neuropathological perspective, the morphology
of VPSPr appears to be consistently similar in the three
PRNP codon 129 genotypes,6 but with differences in the
intensity of the features. This novel prionopathy is charac-
terized by medium-sized microvacuolation affecting most
of the cerebral areas, variable neuronal loss and distinctive
cerebellar molecular layer microplaques. The immunohis-
tochemical PrP pattern also depends on the genotype; it
appears to be more severe in 129VV homozygous patients.
Our case revealed neocortical neuronal loss, deep and
superﬁcial gray matter microvacuolation and cerebellar
microplaques. The immunoproﬁle was consistent with pre-
viously published cases of 129VV VPSPr and revealed tar-
get and dot-like immunoexpression with 12F10 and 3F4.
In addition, BNE stage II Alzheimer type changes were
seen, but no Lewy body pathology was present.
This unexpected case of VPSPr was identiﬁed through a
brain bank donation and was sampled fresh due to the lack
of clinical suggestion of a prionopathy. Several other neuro-
degenerative conditions were considered prior to the prion
immunohistochemistry analysis that allowed the ﬁnal diag-
nosis. It is well known that prionopathies, VPSPr included,
are transmissible neurodegenerative diseases that pose
potential health and safety risks. Although extra health and
safety measurements may be advised in suspected
prionopathies, it is believed that the standard but rigorous
health and safety measures in neuropathology laboratories
and brain banks are sufﬁcient to prevent accidental disease
transmission. Since VPSPr does not fully follow the typical
clinical course for sCJD, it can be expected to occur rarely
in future brain bank donations and may cause diagnostic dif-
ﬁculty, particularly if multiple neurodegenerative processes
are present. The presence of patchy cerebral cortical
spongiform change in the absence of other neurodegenera-
tive pathology should raise the suspicion of VPSPr, even in
elderly patients with a lengthy clinical history.
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